MDM2 overexpression in the absence of MDM2 amplification has been reported in malignant melanoma [50,51,52], Burkitt lymphoma [62], carcinoma of the breast [63,64], carcinoma of the bladder [65], and soft tissue sarcomas [66]. Here, MDM2 is linked to melanoma.